Introduction
Nicotine promotes transmitter release in the brain by a direct action on presynaptic terminals. Pharmacological evidence confirms that this action is mediated by nicotinic acetylcholine receptors (nAChR). The most abundant brain nAChR, the a4B2 subtype, is identified by the binding of tritiated nicotine ([,H]Nic) [ 13. Lesioning and subcellular fractionation studies suggest that the majority of brain high-affinity ['HINic-binding sites may be located presynaptically [2] .
Senile dementia of the Alzheimer's type (SDAT), the most common dementing illness, is a major health problem which will reach epidemic proportions as the percentage of the elderly in the population increases. Although abnormalities in several transmitter systems have been documented in SDAT, the most consistent and pervasive disruption involves the cholinergic system [3] . Postmortem neurochemical studies of Alzheimer brain tissue demonstrate large reductions in the activity of the presynaptic marker enzyme, choline acetyltransferase (ChAT), of up to 68% in the hippocampus [4] . It is well established that a reduction in ChAT activity is correlated with intellectual impairment in memory information tests [ 3 ] . In addition to the ChAT deficit there is a loss of ['HINicbinding sites , consistent with the SDAT pathology of terminal degeneration. A more complete agonist profile of the presynaptic nicotinic receptors in the hippocampus is necessary before these receptors can be targeted therapeutically in the treatment of neurological degeneration.
The aim of this study was to produce a pharmacological profile of the responses of presynaptic nAChR to several agonists, in rat hippocampus. Adult healthy rats were used throughout the study, since it is important to obtain a picture of normal cholinergic function before any attempts are made to model the disease state of cholinergic impairment seen in SDAT. As relatively little is known about which nAChR subtype or subtypes are responsible for modulating feedback of acetyl- choline release in the hippocampus, an additional aim of the study was to compare the pharmacology of these nAChR on cholinergic terminals in the hippocampus, with the pharmacology of a defined a4B2 nAChR stably expressed in the mouse M10 cell line.
Methods
A five-step discontinuous Percoll gradient procedure for isolating synaptosomes [8] yields a preparation enriched in metabolically active, isolated nerve terminals of high purity from relatively small amounts of brain tissue. Hippocampal synaptosomes prepared in this way remain viable for several hours and have been used here to study the presynaptic nicotinic influences on neurotransmitter release.
Hippocampal synaptosomes, prepared as described previously [ 91, were resuspended in Kreb's bicarbonate perfusion medium [composition (mM): NaCI, 118; KCI, 2.35; MgS0,.7H20, 1.2; KH,PO,, 1.2; NaHCO,, 25; CaCI2.2H20, 2.4; Dglucose, 10; gassed with 0 2 / C 0 2 (19:l); pH 7.41, loaded with [3H]choline and superfused [lo] .
[3H]Acetylcholine release was evoked by two sequential 20 s pulses of agonist in perfusion buffer. The two stimulations were given routinely at 45 and 75 min, with a third stimulation using 20 mM K + (KCI isotonically replacing NaCI) administered at 105 min. Each pulse was separated from the bulk flow of the buffer by an air bubble (10 s) on either side. The responses to successive stimulations were designated S1, S2 and S3. Evoked release was determined by subtraction of basal release, and converted to fmol ['HIACh by reference to the specific activity of the ['H]choline used to load the synaptosomes.
Mouse M 10 fibroblast cells expressing stably transfected chicken a4B2 nAChR subunits were cultured and promoted [ l l ] . Activation of nAChR was measured as the stimulation of X6Rb+ into the cells, following treatment with agonist for 1 min [12] . Basal values (XhRb+ influx in the absence of agonist) were subtracted and results from different culture plates in the same assay were normalized with respect to nAChR expression, determined by [ 'Hlcytisine binding. Figure 1 . The bell-shape could reflect nAChR desensitization at high agonist concentrations. When the response to successive agonist stimulations is quantified, using the ratio S2/S1 (Table 1) it is apparent that, with increasing agonist concentration, there is a decrease in the S2/S1 ratio. This result confirms recent reports of high agonist concentration-induced nAChR desensitization [9, 131. Interpretation of the S2/S1 results is confounded by the effects of pool depletion. The radiolabelled ACh is present as a finite pool of transmitter within the synaptosome, a pool which is depleted with time. This is a possible reason for the S2/S1 ratio being less than 1.0, even with the lowest agonist concentrations. It would seem unlikely, however, that pool depletion alone could account for the fall in the S2/S1 ratios seen in the higher agonist concentrations. Several agonists have been compared in both the hippocampal superfusion assay (S 1 stimulation), and a "Rb' flux assay for activation of defined a4B2 nAChR expressed in fibroblasts. In the latter system, dose-responsive curve were similarly bellshaped, suggesting that this could indeed reflect desensitization inherent to the nAChR. ECS, values of agonists in these two preparations are compared in Table 2 .
The agonists used were as follows: ( -)-nicotine from tobacco; cytisine isolated from species of 
Discussion
The nAChR subtype(s) mediating feedback modulation of acetylcholine release in the hippocampus is unknown, but nicotinic stimulation is known to be a a-bungarotoxin-insensitive [ 141, ruling out a major role for the a7 nAChR receptor subtype. The a4P2 subtype, however, is a strong candidate [2], as supported by the loss of [-?H]Nic-binding sites as cholinergic terminals degenerate in SDAT. The comparison between the nAChR-mediated release in the hippocampal superfusion system and M10 a4p2 receptors is consistent with the possibility that the a4B2 receptor is present on cholinergic terminals in the hippocampus, though whether alone or acting in concert with other receptor subtypes it is premature to say.
Cholinergic agonists have long represented a promising therapeutic approach in SDAT [ 151. However, most effort has been focused on muscarinic stimulation and, although nicotine and other agents enhancing cholinergic function appear effective in in Pritro studies such as those outlined here, clinical successes have been complicated by short agonist half-lives, and agonist toxicity. Clearly, the effects of nAChR desensitization lead to a narrow effective dose range or 'therapeutic window'. Doses that exceed this therapeutic window may, in fact, worsen performance on cognitive tests [ 161. Nonetheless, within a narrow therapeutic range, nicotinic agents represent a rational therapeutic approach to SDAT, based on observed neurochemical deficits.
